PT - JOURNAL ARTICLE AU - Rinderknecht, Mike D. AU - Klopfenstein, Yannick TI - Predicting critical state after COVID-19 diagnosis: Model development using a large US electronic health record dataset AID - 10.1101/2020.07.24.20155192 DP - 2020 Jan 01 TA - medRxiv PG - 2020.07.24.20155192 4099 - http://medrxiv.org/content/early/2020/08/31/2020.07.24.20155192.short 4100 - http://medrxiv.org/content/early/2020/08/31/2020.07.24.20155192.full AB - As the COVID-19 pandemic is challenging healthcare systems worldwide, early identification of patients with a high risk of complication is crucial. We present a prognostic model predicting critical state within 28 days following COVID-19 diagnosis trained on data from US electronic health records (IBM Explorys), including demographics, comorbidities, symptoms, insurance types, and hospitalization. Out of 15816 COVID-19 patients, 2054 went into critical state or deceased. Random, stratified train-test splits were repeated 100 times and lead to a ROC AUC of 0.872 [0.868, 0.877] and a precision-recall AUC of 0.500 [0.488, 0.509] (median and interquartile range). The model was well-calibrated, showing minor tendency to overforecast probabilities above 0.5. The interpretability analysis confirmed evidence on major risk factors (e.g., older age, higher BMI, male gender, diabetes, and cardiovascular disease) in an efficient way compared to clinical studies, demonstrating the model validity. Such personalized predictions could enable fine-graded risk stratification for optimized care management.Competing Interest StatementM.R. and Y.K. are employees of IBM Switzerland Ltd.Funding StatementNo third party funding was received for this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The project was approved by the Data Access and Control Board (IBM Watson Health) to further research into COVID-19 for the greater good. Patients in the US opt in by default and need to actively opt out. If the opt out, their data will not be part of the Explorys database used in this work.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe patient data that support the findings of this study are available from IBM Explorys but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available.